Basil M. Hantash, M.D., Ph.D., MBA. founded Escape Therapeutics, Inc. in 2006 and serves as its Chairman of the Board and Chief Executive Officer. Dr. Hantash is an 18-year veteran of regenerative medicine, conducting pioneering research at Stanford University investigating the mechanisms underlying mesenchymal stem cell immune tolerance. He previously served as consulting Chief Scientific Officer of Stemedica Cell Technologies, helping secure Series A financing while guiding technology, regulatory, intellectual property and business development strategies. He was a Partner at Proteus Venture Partners from 2007 to 2009. In 2002, Dr. Hantash founded ZyBas, Inc, a consulting firm focused on supporting early-stage disruptive aesthetic medicine companies such as Reliant Technologies, creators of the breakthrough Fraxel medical laser platform. Prior to this, Dr. Hantash was a research scientist at the neuroscience biotech start-up Molecular Geriatrics. Dr. Hantash completed his dermatology residency, postdoctoral training in the Program for Regenerative Medicine, and a prestigious fellowship in the Biodesign Innovation Program at Stanford University. He received his MD and PhD (pharmacology and physiology) from New Jersey Medical School, where he was inducted in the AOA Medical Honor Society and graduated as valedictorian of both his Graduate and Medical School. Dr. Hantash received his BS in Biology and minor in Chemistry from the University of Illinois, where he was the recipient of a Howard Hughes Research Fellowship. Dr. Hantash completed his MBA with honors at the Wharton School, University of Pennsylvania, where he was also the recipient of the Price Institute Fellowship for entrepreneurship.
Mesenchymal stem cells; Osteogenesis; Adipogenesis; Selection marker; CD 54